Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data
Open Access
- 12 February 2015
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 61 (6) , 1832-1841
Abstract
Existing predictive models of risk of disease progression in chronic hepatitis C have limited accuracy. The aim of this study was to improve upon existing models by applying novel statistical methods that incorporate longitudinal data. Patients in the Hepatitis C Antiviral Long‐term Treatment Against Cirrhosis trial were analyzed. Outcomes of interest were (1) fibrosis progression (increase of two or more Ishak stages) and (2) liver‐related clinical outcomes (liver‐related death, hepatic decompensation, hepatocellular carcinoma, liver transplant, or increase in Child‐Turcotte‐Pugh score to ≥7). Predictors included longitudinal clinical, laboratory, and histologic data. Models were constructed using logistic regression and two machine learning methods (random forest and boosting) to predict an outcome in the next 12 months. The control arm was used as the training data set (n = 349 clinical, n = 184 fibrosis) and the interferon arm, for internal validation. The area under the receiver operating characteristic curve for longitudinal models of fibrosis progression was 0.78 (95% confidence interval [CI] 0.74‐0.83) using logistic regression, 0.79 (95% CI 0.77‐0.81) using random forest, and 0.79 (95% CI 0.77‐0.82) using boosting. The area under the receiver operating characteristic curve for longitudinal models of clinical progression was 0.79 (95% CI 0.77‐0.82) using logistic regression, 0.86 (95% CI 0.85‐0.87) using random forest, and 0.84 (95% CI 0.82‐0.86) using boosting. Longitudinal models outperformed baseline models for both outcomes (P < 0.0001). Longitudinal machine learning models had negative predictive values of 94% for both outcomes. Conclusions: Prediction models that incorporate longitudinal data can capture nonlinear disease progression in chronic hepatitis C and thus outperform baseline models. Machine learning methods can capture complex relationships between predictors and outcomes, yielding more accurate predictions; our models can help target costly therapies to patients with the most urgent need, guide the intensity of clinical monitoring required, and provide prognostic information to patients. (Hepatology 2015;61:1832–1841)Keywords
Funding Information
- Foundation for the National Institutes of Health (T32DK062708)
- Foundation for the National Institutes of Health (R01 GM097117)
- U.S. Department of Veterans Affairs (1IK2HX000775)
This publication has 20 references indexed in Scilit:
- Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2013
- Comparison of imputation methods for missing laboratory data in medicineBMJ Open, 2013
- Does Antiviral Therapy Prevent Hepatocellular Carcinoma?Antiviral Therapy, 2011
- Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis CGastroenterology, 2011
- Evolving epidemiology of hepatitis C virusClinical Microbiology and Infection, 2011
- Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infectionJournal of Viral Hepatitis, 2010
- Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis CGut, 2010
- Algorithms Outperform Metabolite Tests in Predicting Response of Patients With Inflammatory Bowel Disease to ThiopurinesClinical Gastroenterology and Hepatology, 2010
- Role of simple biomarkers in predicting fibrosis progression in HCV infectionWorld Journal of Gastroenterology, 2010
- Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespondersControlled Clinical Trials, 2004